Welcome to our dedicated page for ARVINAS SEC filings (Ticker: ARVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ARVINAS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ARVINAS's regulatory disclosures and financial reporting.
Arvinas, Inc. granted equity awards to director Linda Bain. She received 15,527 restricted stock units, each representing one share of common stock for no cash consideration. Following the grant, she directly holds 41,572 common shares.
Bain was also granted stock options for 22,714 shares at an exercise price of $8.05 per share, expiring on June 23, 2036. Both the RSUs and options vest in full on the earlier of June 24, 2027 or immediately before the first annual meeting of stockholders after the grant date, subject to her continued service with Arvinas.
Arvinas, Inc. held its annual meeting of stockholders on June 24, 2026, where three proposals were put to a vote. Stockholders elected Class II directors Leslie V. Norwalk, Esq. and Randy Teel, Ph.D. to serve until the 2029 annual meeting of stockholders. They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. In addition, stockholders ratified the appointment of Deloitte & Touche LLP as Arvinas’ independent registered public accounting firm for the fiscal year ending December 31, 2026.
ARVINAS, INC. Chief Financial Officer Andrew Saik reported an automatic sale of 5,696 shares of common stock at $8.159 per share. The sale was made by the company to cover tax withholding obligations tied to the vesting and settlement of 25% of his restricted stock units granted on June 24, 2024, under a durable sale instruction, and was not a discretionary trade. After this transaction, he continues to hold 187,432 shares of common stock directly.
Arvinas, Inc. reports the proposed sale/settlement of 5,846 shares of Common Stock tied to the settlement of vested restricted stock units, scheduled to settle on 06/24/2026 through Morgan Stanley Smith Barney LLC. The excerpt also shows a prior disposition of 11,139 shares by Andrew Saik on 05/11/2026.
Arvinas, Inc. announced that chief medical officer Noah Berkowitz, M.D., Ph.D. will leave the company, with his employment ending on July 3, 2026. He is expected to remain in his role until that date while the company searches for a new chief medical officer.
Under a separation agreement signed on June 22, 2026, Dr. Berkowitz receives nine months of base-salary continuation, up to nine months of company-paid health premiums, and accelerated vesting of certain restricted stock units scheduled to vest on or before May 9, 2027, with remaining awards forfeited.
Arvinas, Inc. Chief Scientific Officer Angela M. Cacace reported an automatic sale of 2,576 shares of common stock at $7.595 per share. According to the disclosure, the issuer executed this sale to cover tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units, under a durable sale instruction, and it was not a discretionary trade. Following the transaction, Cacace directly holds 180,390 shares of Arvinas common stock.
Arvinas, Inc. reports the settlement and planned sale of 2,642 common shares on 06/17/2026 arising from vested restricted stock units through Morgan Stanley Smith Barney LLC on the NASDAQ.
Separately, the filing shows an earlier sale by Angela Cacace of 9,657 common shares on 05/11/2026 for $95,965.47. The notice lists the securities type as Common and states the transaction method as Settlement of vested restricted stock units.
Arvinas, Inc. reports that its license agreement with Rigel Pharmaceuticals and Pfizer for VEPPANU (vepdegestrant) is now effective after early Hart-Scott-Rodino antitrust clearance. Rigel has paid an aggregate $70.0 million upfront to Arvinas and Pfizer.
The partners are eligible for an additional $15.0 million upon completion of certain development and manufacturing transition work, and up to $320.0 million in future development, regulatory and commercial milestone payments, plus tiered mid-teens to mid-20s royalties on worldwide VEPPANU sales. All payments are to be split evenly between Arvinas and Pfizer, replacing unearned future amounts under their 2021 collaboration.
Arvinas, Inc. filed a current report outlining a portfolio re‑prioritization and updated plans for its ARV-806 program, along with an investor presentation for use at the Jefferies Global Healthcare Conference and other meetings.
After a strategic review, the company plans to complete the ongoing Phase 1 monotherapy dose escalation trial of ARV-806 in patients with solid tumors harboring KRAS G12D mutations and share clinical data in 2026. For any further development, such as dose expansion or combination trials, Arvinas intends to seek an out-licensing partner rather than advance ARV-806 alone. The company also reiterates that its cash, cash equivalents and marketable securities as of March 31, 2026 are expected to fund planned operating and capital spending into the second half of 2028.
ARVINAS, INC. President and CEO Randy Teel reported an automatic sale of 2,209 shares of common stock at $9.0365 per share. According to the footnote, the shares were sold by the company to cover tax withholding obligations tied to the vesting of RSUs granted on May 21, 2024, and the transaction was not a discretionary trade. After this tax-related sale, Teel directly holds 285,009 shares of Arvinas common stock.